Equities research analysts expect Stericycle Inc (NASDAQ:SRCL) to report sales of $862.21 million for the current quarter, Zacks reports. Seven analysts have made estimates for Stericycle’s earnings, with estimates ranging from $848.50 million to $885.30 million. Stericycle reported sales of $882.77 million during the same quarter last year, which would suggest a negative year over year growth rate of 2.3%. The firm is scheduled to report its next quarterly earnings report on Wednesday, November 14th.

On average, analysts expect that Stericycle will report full year sales of $3.51 billion for the current fiscal year, with estimates ranging from $3.47 billion to $3.58 billion. For the next financial year, analysts expect that the business will report sales of $3.55 billion per share, with estimates ranging from $3.49 billion to $3.61 billion. Zacks’ sales averages are an average based on a survey of research analysts that follow Stericycle.

Stericycle (NASDAQ:SRCL) last released its quarterly earnings data on Thursday, August 2nd. The business services provider reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.04. Stericycle had a return on equity of 14.04% and a net margin of 5.03%. The firm had revenue of $883.30 million during the quarter, compared to analyst estimates of $896.62 million. During the same period in the prior year, the company posted $1.15 earnings per share. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year.

Several analysts have recently commented on SRCL shares. Zacks Investment Research upgraded Stericycle from a “hold” rating to a “buy” rating and set a $73.00 target price on the stock in a report on Friday, July 6th. BMO Capital Markets decreased their target price on Stericycle from $71.00 to $63.00 and set a “market perform” rating on the stock in a report on Monday, August 6th. Jefferies Financial Group set a $75.00 target price on Stericycle and gave the stock a “buy” rating in a report on Thursday, August 2nd. BidaskClub upgraded Stericycle from a “hold” rating to a “buy” rating in a report on Tuesday, July 3rd. Finally, Barrington Research restated a “buy” rating on shares of Stericycle in a report on Friday, June 1st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. Stericycle currently has a consensus rating of “Hold” and a consensus price target of $71.71.

Stericycle stock opened at $61.87 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 0.81 and a quick ratio of 0.81. Stericycle has a 52-week low of $56.64 and a 52-week high of $76.73. The firm has a market cap of $5.26 billion, a price-to-earnings ratio of 13.95, a P/E/G ratio of 1.42 and a beta of 0.36.

In related news, Director Mark C. Miller sold 65,314 shares of the firm’s stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $65.08, for a total value of $4,250,635.12. Following the transaction, the director now owns 224,052 shares in the company, valued at $14,581,304.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark C. Miller sold 95,227 shares of the firm’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $65.05, for a total value of $6,194,516.35. Following the completion of the transaction, the director now owns 257,488 shares in the company, valued at approximately $16,749,594.40. The disclosure for this sale can be found here. Insiders have sold 170,601 shares of company stock worth $11,153,063 in the last 90 days. Company insiders own 3.50% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Cornerstone Wealth Management LLC bought a new position in Stericycle in the second quarter valued at about $222,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Stericycle by 8.3% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 45,631 shares of the business services provider’s stock valued at $2,979,000 after acquiring an additional 3,500 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in Stericycle by 30.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 8,615 shares of the business services provider’s stock valued at $562,000 after acquiring an additional 2,025 shares during the last quarter. Brown Advisory Inc. boosted its holdings in Stericycle by 273.3% in the second quarter. Brown Advisory Inc. now owns 39,477 shares of the business services provider’s stock valued at $2,577,000 after acquiring an additional 28,903 shares during the last quarter. Finally, Reinhart Partners Inc. bought a new position in Stericycle in the second quarter valued at about $15,474,000. Institutional investors and hedge funds own 95.46% of the company’s stock.

Stericycle Company Profile

Stericycle, Inc, together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States and internationally. It collects and processes regulated and specialized waste for disposal services; and collects personal and confidential information for secure destruction, as well as offers training, consulting, recall/return, communication, and compliance services.

Read More: Outstanding Shares

Get a free copy of the Zacks research report on Stericycle (SRCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stericycle (NASDAQ:SRCL)

Receive News & Ratings for Stericycle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stericycle and related companies with MarketBeat.com's FREE daily email newsletter.